BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 23331787)

  • 1. The evolution of treatment for Wilms tumor.
    Green DM
    J Pediatr Surg; 2013 Jan; 48(1):14-9. PubMed ID: 23331787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
    Fernandez CV; Mullen EA; Chi YY; Ehrlich PF; Perlman EJ; Kalapurakal JA; Khanna G; Paulino AC; Hamilton TE; Gow KW; Tochner Z; Hoffer FA; Withycombe JS; Shamberger RC; Kim Y; Geller JI; Anderson JR; Grundy PE; Dome JS
    J Clin Oncol; 2018 Jan; 36(3):254-261. PubMed ID: 29211618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is radiotherapy required in first-line treatment of stage I diffuse anaplastic Wilms tumor? A report of SIOP-RTSG, AIEOP, JWiTS, and UKCCSG.
    Fajardo RD; van den Heuvel-Eibrink MM; van Tinteren H; Spreafico F; Acha T; Bergeron C; de Camargo B; Oldenburger F; Rübe C; Oue T; Vokuhl C; de Krijger RR; Vujanic G; Sebire N; Coulomb-L'Hermine A; Collini P; Gandola L; Pritchard-Jones K; Graf N; Janssens GO; van Grotel M
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28039. PubMed ID: 31625685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Wilms' tumor: reached progress and future prospects].
    Tamaro P
    Arch Ital Urol Androl; 1997 Sep; 69(4):227-32. PubMed ID: 9417294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remaining problems in the treatment of patients with Wilms' tumor.
    Green DM; Finklestein JZ; Breslow NE; Beckwith JB
    Pediatr Clin North Am; 1991 Apr; 38(2):475-88. PubMed ID: 1848690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcomes in adults with favorable histologic type Wilms tumor-an update from the National Wilms Tumor Study Group.
    Kalapurakal JA; Nan B; Norkool P; Coppes M; Perlman E; Beckwith B; Ritchey M; Breslow N; Grundy P; D'angio GJ; Green DM; Thomas PR
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1379-84. PubMed ID: 15590168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
    Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
    J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bilateral Wilms tumors: Treatment results from a single center.
    Aydın B; Akyüz C; Yalçın B; Ekinci S; Oğuz B; Akçören Z; Yıldız F; Varan A; Kurucu N; Büyükpamukçu M; Kutluk T
    Turk J Pediatr; 2019; 61(1):44-51. PubMed ID: 31559721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report.
    Dix DB; Fernandez CV; Chi YY; Mullen EA; Geller JI; Gratias EJ; Khanna G; Kalapurakal JA; Perlman EJ; Seibel NL; Ehrlich PF; Malogolowkin M; Anderson J; Gastier-Foster J; Shamberger RC; Kim Y; Grundy PE; Dome JS;
    J Clin Oncol; 2019 Oct; 37(30):2769-2777. PubMed ID: 31449468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study.
    Messahel B; Williams R; Ridolfi A; A'hern R; Warren W; Tinworth L; Hobson R; Al-Saadi R; Whyman G; Brundler MA; Kelsey A; Sebire N; Jones C; Vujanic G; Pritchard-Jones K;
    Eur J Cancer; 2009 Mar; 45(5):819-26. PubMed ID: 19231157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
    Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
    Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
    Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
    Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wilms' tumor in the adult--report of a case and review of the literature.
    Tawil A; Cox JN; Roth AD; Briner J; Droz JP; Remadi S
    Pathol Res Pract; 1999; 195(2):105-11; discussion 113-4. PubMed ID: 10093830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of the United Kingdom Children's Cancer Study Group first Wilms' Tumor Study.
    Pritchard J; Imeson J; Barnes J; Cotterill S; Gough D; Marsden HB; Morris-Jones P; Pearson D
    J Clin Oncol; 1995 Jan; 13(1):124-33. PubMed ID: 7799012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wilms' tumor- roadmaps of management.
    Sarin YK; Bhatnagar SN
    Indian J Pediatr; 2012 Jun; 79(6):776-86. PubMed ID: 22555907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of blastemal predominant histology in initially resected Wilms' tumors: a report from the Study Group for Pediatric Solid Tumors in the Kyushu Area, Japan.
    Kinoshita Y; Suminoe A; Inada H; Yagi M; Yanai F; Zaizen Y; Nishi M; Inomata Y; Kawakami K; Matsufuji H; Suenobu S; Handa N; Kohashi K; Oda Y; Hara T; Taguchi T
    J Pediatr Surg; 2012 Dec; 47(12):2205-9. PubMed ID: 23217877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group.
    Mitchell C; Pritchard-Jones K; Shannon R; Hutton C; Stevens S; Machin D; Imeson J; Kelsey A; Vujanic GM; Gornall P; Walker J; Taylor R; Sartori P; Hale J; Levitt G; Messahel B; Middleton H; Grundy R; Pritchard J;
    Eur J Cancer; 2006 Oct; 42(15):2554-62. PubMed ID: 16904312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity of disease classified as stage III in Wilms tumor: a report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).
    Spreafico F; Gandola L; D'Angelo P; Terenziani M; Collini P; Bianchi M; Provenzi M; Indolfi P; Pession A; Nantron M; Di Cataldo A; Marchianò A; Catania S; Fossati Bellani F; Piva L;
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):348-54. PubMed ID: 21075548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse of unilateral favorable histology Wilms' tumor: significant clinicopathological factors.
    Aoba T; Urushihara N; Fukumoto K; Furuta S; Fukuzawa H; Mitsunaga M; Watanabe K; Yamoto M; Miyake H; Koyama M; Iwabuchi H; Koike J; Tatsunami S; Wakisaka M; Kitagawa H
    J Pediatr Surg; 2012 Dec; 47(12):2210-5. PubMed ID: 23217878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of the Sixth International Society of Pediatric Oncology Wilms' Tumor Trial and Study: a risk-adapted therapeutic approach in Wilms' tumor.
    Tournade MF; Com-Nougué C; Voûte PA; Lemerle J; de Kraker J; Delemarre JF; Burgers M; Habrand JL; Moorman CG; Bürger D
    J Clin Oncol; 1993 Jun; 11(6):1014-23. PubMed ID: 8388918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.